Prostate cancer (PCa) is a major health issue in Westernized countries, representing a common cause of morbidity and mortality in the elderly male population. Endogenous sex steroids, along with environmental factors (notably diet) and host immune and inflammatory responses, are likely to cooperate in the pathogenesis of the disease. Based on the assumption that a complex endocrine-inflammatory-immune interaction is primarily implicated in human PCa, we have investigated the interplay between sex steroids and inflammation in development and growth of human PCa. To this end, we have assessed nine functional single nucleotide polymorphisms (SNP)s of five genes involved in sex hormone-related pathways in both hyperplastic and malignant human prostate tissues, as well as in matched controls and in a ''supercontrol'' group composed of male Sicilian centenarians. In particular, the following genes were investigated:
Introduction

S
ex steroid hormones are generally believed to play a critical role in the complex pathophysiology of human PCa (Caruso et al., 2009; Ellem and Risbridger, 2010; Ricke et al., 2007) . Androgens are primarily responsible for development and function of human prostate gland, as well as for the maintenance of homeostasis of prostate tissues in the adulthood. The major prostatic androgens are the testosterone and its derivative dihydrotestosterone, produced locally through the 5a-reductase enzyme. Most of their effects are mediated by binding to androgen receptors (AR). Androgens also represent well-established risk factors for development and progression of benign and malignant disorders of prostate gland (Ricke et al., 2007) .
Today there is accumulating evidence suggesting that estrogens play a crucial role in both normal and diseased human prostate (Carruba, 2007; Risbridger, 2009, 2010; McPherson et al., 2008) . In particular, a combined action of androgens and estrogens and their balance appear to be critically important in maintaining prostate health and tissue
homeostasis. An alteration of this balance has been recently implicated in the development of both benign and malignant diseases, including PCa Risbridger, 2009, 2010) .
Aging men have unchanged or increased circulating levels of estradiol, as opposed to the decline of plasmatic testosterone. Estrogen production is maintained through aromatization of adrenal androgens driven by the aromatase enzyme, especially in peripheral adipose tissue (Ellem and Risbridger, 2010) . In normal prostate gland, the aromatase enzyme is expressed within the stroma, while the malignant prostate show an aberrant aromatase expression in the epithelial compartment (Ellem and Risbridger, 2010) . This withdraws circulating testosterone and results in a significant reduction of plasma testosterone to estradiol ratio that has been associated to an increased risk of developing PCa (Carruba, 2007) .
The estrogen role in human prostate is further complicated by the differential expression and activity of the two estrogen receptors (ER), a and b Risbridger, 2009, 2010) . A sustained activation of ERa may eventually lead to an aberrant proliferation, inflammation and to development of premalignant lesions. In contrast, ERb appears to have antiproliferative effects and to exert a protective role against prostate carcinogenesis Risbridger, 2009, 2010) .
Despite the above evidence, many epidemiologic studies have failed to show a significant association between circulating sex steroids and prostate cancer risk (Crawford, 2009; Plaza and Giovannucci, 2004) . Undoubtedly, several issues related to measurement of plasma steroids, both androgens and estrogens, should be considered to explain this large inconsistency of data. However, the ethnic variability and the heterogeneity of genetic background among the individuals may well have a major impact. In particular, single nucleotide polymorphisms (SNPs) of genes involved in both metabolism and action of steroid hormones may be primarily implicated. An association between PCa risk and SNPs of genes whose products are involved in sex hormone-related steroid pathways has been observed (Chae et al., 2009; Cussenot et al., 2007; Dianat et al., 2009; Huhtaniemi et al., 2010; Mononen and Schleutker, 2009) .
Based on the hypothesis that both individual and combined variations in genes that govern local bioavailability and action of sex steroids can modify the individual susceptibility to PCa, we have investigated nine selected SNPs of five genes (AR-OMIM313700, SRD5A2-NM 000348, CYP19-NM-031226, ERS1-NM-001122742. ERS2-NM-001040276) involved in sexrelated hormone pathways, comparing subjects having hyperplastic and malignant prostate, healthy controls, and male centenarians from Sicily. This latter represents a supercontrol group, consisting of ''exceptional individuals'' who have been able to escape major common age-related diseases, including cancer (Cevenini et al., 2008; Imyanitov, 2009 ).
Subjects and Methods
Patients and controls
The study included 50 Sicilian patients having hyperplastic (32%) and malignant prostate (68%) lesions recruited at the time of diagnosis (age range: 60-80 years). Controls were 47 healthy male Sicilians according to their clinical history and blood tests. A second control group consisted of 44 male centenarians (>99 years), whose age was confirmed from records at the city hall and/or church registries. No cancer or other age-related diseases were clinically detectable in the centenarians, although some had reduced auditory and visual acuity. Because immigration and intermarriage have historically been rare in the last hundred years, the ethnicity of all participants was established by all four grandparents having been born in Sicily. The study received approval from local ethic committees and all participants gave their written informed consent.
Genotyping
The study material consisted of DNA samples. The DNA samples of both hyperplastic and cancer cases were obtained from prostate tissue biopsies placed into a suitable volume of RNA-later (RNA Stabilization Reagent, Applied Biosystems, Foster City, CA, USA) to avoid RNA degradation. The DNA samples of the two control groups were extracted from peripheral blood using salting out method (Miller et al., 1998) . Genomic DNA and total RNA were purified simultaneously from each sample using an All-Prep DNA/RNA Mini Kit (Qiagen, Dusseldorf, Germany). Samples were genotyped for nine SNPs of the selected genes, as reported in b T1 Table 1 . For genotyping, the procedure used was based on the Restriction Fragment-Length Polymorphism-PCR (RFLP-PCR), cleavage with specific restriction enzymes and separation of DNA fragments by electrophoresis, as described in literature data.
Statistics
Allelic and genotypic frequencies were evaluated by gene count. The data were tested for the goodness of fit between the observed and expected genotype frequencies, according to Hardy-Weinberg equilibrium, by chi-square test. Significant differences in frequencies among the three groups were calculated by w 2 (by 3Â3, 3Â2, and 2Â2 tables, where appropriate).
Results
When comparing the genotype distribution and allele frequencies of the nine SNPs selected in the three cohorts of subjects, significant differences were observed for the following SNPs: AR þ211G/A, SRD5A2 A49T, CYP19Arg264Cys,
Tables 2 and b T3 3, respectively). As illustrated in the Table 2, significant differences were found ( p ¼ 0.01, by chi-square test, 3Â3 table) in the genotype distribution of AR þ211G/A SNP among the three groups. Significant differences were also observed between patients and matched controls ( p ¼ 0.04), and between patients and centenarians ( p ¼ 0.03). In addition, a high frequency of the AR þ211A allele expression was found in the three groups ( p ¼ 0.0009 by chi-square test with Yates's correction, 2Â3 table), and in patients respect to matched controls and centenarians ( p ¼ 0.005 and p ¼ 0.003, respectively, by chi-square test with Yates's correction, 2Â2 table) (Table 3) .
Concerning the two SNPs (A49T and V89L) of the gene encoding the 5a-reductase enzyme (SRD5A2), significant differences were observed in genotype distribution of SRD5A2 A49T among the three groups ( p ¼ 0.000008) ( Table 2 ). Significant differences were also revealed between patients and matched controls ( p ¼ 0.0003), and between patients and centenarians ( p ¼ 0.00003) ( Table 2 ). Accordingly, an overexpression of SRD5A2 49T allele was evidenced in the three groups ( p ¼ 0.0000009 by chi-square test with Yates's correction, 2Â3 table), and in patients with respect to both matched controls and centenarians ( p ¼ 0.0000001, by chi-square test with Yates's correction, 2Â2 table) (Table 3) .
Concerning the three SNPs selected of the aromatase-CYP19 gene, significant differences were revealed in genotype distribution of CYP19Arg264Cys among the three groups ( p ¼ 0.01) ( Table 3) . No significant differences both in the genotype distribution and allele frequency of CYP19-39Trp/Arg among the three cohorts were evidenced (data no shown). As reported in Table 2 , significant differences were also obtained in genotype distributions and allele frequencies of ERS1-351A/G and À397T/C SNPs. In particular, significant differences were observed in the genotype distribution of ERS1-351A/G among the three groups ( p ¼ 0.001), between patients and matched controls ( p ¼ 0.03) and between patients and centenarians ( p ¼ 0.0009). Accordingly, an overexpression of the ERS1-351G allele was observed among the three groups ( p ¼ 0.0001 by chi-square test with Yates's correction, 2Â3 It is a silent SNP in exon 10, corresponding to the 3 0 untranslated region of mRNA; it has been proposed as functionally relevant, because it is correlated to level of aromatase mRNA in tumor cells. Located in the codon 39Trp/arg, it is significantly associated with PCa. Located in the exon 7, it determines the C to T substitution in the position of nucleotide 826, resulting in the substitution from Arg to CYs at codon 264. It has been associated with an increased risk of PCa ERa, ESR1 A351G, rs: 9340799 T397C, rs: 2234693 351A/G (or Xba I) and 397T/C (or PvuII), most widely studied SNPs of ER1 gene, seem to be in linkage disequilibrium. They have been associated with higher risk of prostate cancer. Concerning the XbaI SNP, higher circulating levels of androstenedione have been observed in A/A (or x/x genotype) The polymorphism IVS1-397 was described as a C-to-T change in the intron of estrogen receptor (located at position 397 before exon 2; http://genome.ucsc.edu). The substitution of T generates a sequence, which can be cut by ESR1 IVS1-397 T/C (PvuII) (CAG/CTGcomplementary strand). This SNP has been associated with estrogen-dependent diseases. The clinical data indicate that carriage of this SNP has functional consequences by influencing ESR ligand binding and local estrogenic action ERb, ESR2 G1082A, (no rs available designation)
It has been reported to be associated with increased estrogen dysfunction.
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Concerning the ERS2-1082G/A SNP, significant differences were also found in genotype distribution of among the three groups ( p ¼ 0.0001 by chi-square test, 3Â3 In our study the hyperplastic (16) and malignant (34) cases were included in the same group, because the analysis of the data in the separated cohorts (hyperplastic and malignant cases) compared to two control groups did not demonstrate any difference.
In summary, the alleles associated with increased PCa risk were overrepresented in patients compared to healthy men and to centenarians.
Discussion and Conclusion
The molecular pathology of PCa is intricate. Endogenous sex steroids along with environmental factors (e.g., diet) and 
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host immune and inflammatory responses are likely to cooperate in the pathogenesis of this neoplastic disease (Caruso et al., 2009; De Marzo et al., 2007) . Based on this assumption, we have analyzed the association between PCa and nine functional SNPs of the AR, SRD5A2, CYP19, ERS1 e ERS2 genes involved in sex hormone pathways. Our results suggest the potential association of seven out of nine SNPs with PCa. They also reveal that most of the selected alleles are underrepresented in centenarians, used in our study as an additional supercontrol group of ''exceptional individuals'' free of major common age-related diseases, including cancer (Cevenini et al., 2008; Imyanitov, 2009) .
Our data also imply that alleles associated with age-related diseases, including PCa, are not prominent in the genetic profile favouring longevity, as indicated in our previous studies (Candore et al., 2007a (Candore et al., , 2007b . Based on this evidence, one could speculate that the genes selected in our study may function in an antagonistically pleiotropic manner. They exert a beneficial role in younger age maintaining growth and homeostasis of the prostate gland, while they play a detrimental role producing an aberrant cell proliferation, inflammation and the development of premalignant and malignant lesions later in life.
The mechanisms underpinning the putative role of the selected alleles in the development and/or progression of PCa during the aging process, however, remain unknown. Larger studies are needed to confirm the findings of this preliminary report and to get insights into relevant mechanisms, with special emphasis on local metabolism and action of either androgens or estrogens. It should be noted that circulating sex steroids cannot be considered representative of their intraprostatic levels that strictly depends upon expression and activity of key enzymes governing local metabolism and biotransformation (Carruba, 2007) . In this respect, the appraisal of steroid enzymes (such as aromatase and 5-a reductase) and receptors (such as AR, ERa and ERb), that respectively determine metabolic profiles and signaling in both normal and diseased human prostate, is crucially important to associate sex hormone-related pathways and PCa risk. In this framework, our data, although preliminary, might provide an important experimental basis to develop additional or alternative strategies for prevention and treatment of human PCa. 
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